Stroke Research
Stroke is classified as both a neurological and a cardiovascular disease, as it is a disruption in blood supply to the brain which causes the neurological abnormalities. There are two types of stroke; ischemic and hemorrhagic.
Stroke Research Products Targets
- Adenosine A2B Receptor (7)
- Adenosine A2A Receptor (11)
- Caspase (9)
- Voltage-gated Sodium (NaV) Channel (30)
- Voltage-gated Potassium (KV) Channel (38)
- Voltage-gated Calcium Channel (CaV) (38)
- Lipoxygenase (8)
- Others (20)
- Cyclooxygenase (24)
- Epithelial Sodium Channel (3)
- STIM-Orai Channel (4)
- Ryanodine Receptor (6)
- Natriuretic Peptide Receptor (4)
- 5-HT7 Receptor (11)
- 5-HT6 Receptor (14)
- 5-ht5 Receptor (2)
- 5-HT4 Receptor (17)
- Glutamate (Metabotropic) Group III Receptor (26)
- Glutamate (Metabotropic) Group II Receptor (33)
- Glutamate (Metabotropic) Group I Receptor (54)
- AMPA Receptor (45)
- GABAA-ρ Receptor (8)
- GABAA Receptor (66)
- NMDA Receptor (87)
- Kainate Receptor (22)
- IP3 Receptor (2)
- Glutamate Transporter (18)
- Adenosine A3 Receptor (8)
- Adenosine A1 Receptor (12)
- Acid-Sensing Ion Channel (3)
- Calcium-Activated Potassium (KCa) Channel (19)
- Calcium-Sensitive Protease Modulator (12)
- Inward Rectifier Potassium (Kir) Channel (21)
- NO donors and precursors (9)
- nNOS (5)
- iNOS (11)
- eNOS (1)
- Prostanoid Receptor (24)
Products for Stroke Research - Page 51
- Cat.No. Product Name Information/Activity
-
BCC7936
VU 29
890764-36-0
-
BCC6969
(2R,4R)-APDC
(2R,4R)-APDC is a selective group II metabotropic glutamate receptors (mGluRs) agonist. (2R,4R)-APDC has anticonvulsant and neuroprotective effects.
-
BCC6609
L-CCG-l
117857-93-9
-
BCC5691
DCG IV
DCG-IV is a potent agonist of group II mGluRs with EC50s of 0.35 and 0.09 μM for mGlu2R and mGlu3R, reapectively. DCG-IV is also a competitive antagonist at group I (IC50: mGlu1/5R=389/630 μM) and III receptors (IC50: mGlu4/6/7/8R= 22.5/39.6/40.1/32 μM). DCG-IV has anticonvulsive and neuroprotective effects.
-
BCC7614
LY 354740
Eglumegad (LY354740) is a highly potent and selective group II (mGlu2/3) receptor agonist with IC50s of 5 and 24 nM on transfected human mGlu2 and mGlu3 receptors, respectively.
-
BCC7368
LY 379268
Highly selective group II mGlu agonist
-
BCC7623
(±)-LY 395756
852679-66-4
-
BCC6758
MAP4
157381-42-5
-
BCC6925
(RS)-APICA
170847-18-4
-
BCC6871
EGLU
EGLU ((2S)-α-Ethylglutamic acid; (2S)-α-EGLU) is a potent and competitive mGluR-2 receptor antagonist. EGLU interacts with (lS,3S)-ACPD-sensitive site with a Kd value of 66 μM. EGLU is an antidepressant agent.
